Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spero TherapeuticsSPRO -0.41%44 Price-to-Tangible-Book is 1.59 as of Sep. 05, 2026. GuruFocus rates SPRO with a GF Score™ of 44/100 and a GF Value™ of $0.80 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,131 Biotechnology companies, Spero Therapeutics ranks better than 77.01% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Spero Therapeutics Price-to-Tangible-Book Related Terms
Spero Therapeutics Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Spero Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SPRO vs XBIT, MNOV, PLRX: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Spero Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Spero Therapeutics (SPRO) has a Price-to-Tangible-Book of 1.59 as of Sep. 05, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Spero Therapeutics and its competitors. According to the industry distribution chart, Spero Therapeutics ranks #260 out of 1131 companies in the Biotechnology industry, placing it in the top 23%.
Is Spero Therapeutics' Price-to-Tangible-Book too high?
Spero Therapeutics' current Price-to-Tangible-Book is 1.59. The Biotechnology industry median Price-to-Tangible-Book is 3.26. Spero Therapeutics' value of 1.59 is 51.2% below this industry median. Based on the distribution chart, Spero Therapeutics ranks #260 out of 1131 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Spero Therapeutics has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spero Therapeutics' Price-to-Tangible-Book compare to XBIT and MNOV?
According to the Biotechnology industry distribution chart, Spero Therapeutics ranks #260 out of 1131 companies for Price-to-Tangible-Book. This places Spero Therapeutics in the top 23% of its industry — outperforming the majority of peers. The industry median Price-to-Tangible-Book is 3.26. Spero Therapeutics' value of 1.59 is 51.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.26, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spero Therapeutics's current Price-to-Tangible-Book of 1.59 is 51.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Spero Therapeutics and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spero Therapeutics's current Price-to-Tangible-Book is 1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (SPRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.80, compared to a current price of $1.21 — trading 51.3% above its estimated fair value. The current Price-to-Tangible-Book is 1.59 and 51.2% below the Biotechnology industry median of 3.26. Spero Therapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Spero Therapeutics (SPRO), the current Price-to-Tangible-Book is 1.59 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spero Therapeutics (SPRO) Overvalued in 2026?
Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued.
The current stock price of $1.21 is trading 51.3% above its estimated GF Value™ of $0.80.
GuruFocus considers Spero Therapeutics to be Significantly Overvalued.
Key valuation signals for SPRO:
Price-to-Tangible-Book: 1.59
GF Value™: $0.80 vs. price of $1.21 (51.3% above fair value)
Industry Position: 51.2% below the Biotechnology median (#260 of 1131)
No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
44GF Score
Get the complete analysis for SPRO
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRO has been successfully added to your 
